Twist Bioscience Entered into Antibody Discovery and Licensing Option Agreement with Bayer to Advance Drug Discovery
Shots:
- Twist will receive fees for the initiation of research and will be eligible to receive research milestones and the exercise of licensing options, ~$188M in clinical and commercial milestones along with royalties
- Under the terms of the agreement, Bayer gets an exclusive right to license the Abs for commercialization in all global territories. The collaboration will combine both companies’ scientific and technical strengths to identify and develop new therapies in multiple disease areas
- Twist Biopharma Solutions, a division of Twist Bioscience will be responsible for conducting Ab discovery campaigns against targets to be determined by Bayer using its Library of Libraries
Ref: Businesswire | Image: Twist
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
